CC Community News Digest (week of September 14-20)

Assorted news from the last week:

A study by a French research team found “that treatment with growth hormones is not associated with an increased risk of second tumors” for children who survived cancer and later received treatment for growth hormone deficiency.

Brigitte Widemann, chief of the Pediatric Oncology Branch for the Center for Cancer Research at the National Cancer Institute, started conducting clinical trials for neurofibromatosis type 1 (NF1) in 2001, and results from the most recent trial holds promise to shrink the tumors or stop their growth.

FDA grants rare pediatric disease designation to a second CAR (chimeric antigen receptor) T-cell therapy programmed to destroy cells with a surface marker called CD22.  This treatment is intended for children and young adults whose ALL has relapsed after or is resistant to immunotherapy directed toward another surface molecule, CD19.

New release this week in NCI’s Childhood Cancer Video Series:  “When a Child Has Cancer.”  Check out the entire series of short videos featuring parents and pediatric oncology experts sharing strategies to help parents cope with a diagnosis of childhood cancer, make treatment-related decisions, support their child and family, and manage cancer information.

In conjunction with Childhood Cancer Awareness Month, Healio (a specialty clinical information website) rounds up eight key updates in pediatric oncology research and treatment.

SpringWorks Therapeutics Announces Collaboration with Children’s Oncology Group to Conduct a Phase 2 Clinical Trial of Nirogacestat in Pediatric Patients with Desmoid Tumors.

FDA granted Rare Pediatric Disease Designation to Ad-RTS-hIL-12 with veledimex (Controlled IL-12) for the investigational treatment of DIPG.

A new study of cancer in adolescents and young adults (AYAs) showed that cancer incidence is highest among non-Hispanic whites, cancer mortality is highest among non-Hispanic Blacks, and that cancers in AYAs may be molecularly distinct from cancers in younger and older patients.

Upcoming webinars: